Entrectinib is an investigational therapy designed
to target specific causes of certain types of cancer, specifically
rearrangements or “fusions” of the NTRK1, NTRK2, NTRK3, ROS1, and ALK genes (visit Ignyta.com to learn more about the relationship between gene fusions and cancer formation).
Ignyta’s STARTRK-2 trial of entrectinib is now recruiting patients with fusions of the ROS1, ALK, and NTRK
genes. Your doctor can order a no-cost test to see if your cancer has
these gene fusions, and if you are a candidate for the STARTRK-2
clinical trial. This test, in most cases, can be performed on a tumor
sample that was previously obtained and stored, avoiding the need for a
new biopsy.
Check this out at https://www.startrktrials.com/
No comments:
Post a Comment